

ASX Announcement

Vietnamese Patent Granted for RECCE® Anti-Infectives

Sydney Australia, 14 July 2026: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**) (**Recce or the Company**), a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to announce the Intellectual Property Office of Vietnam (IP Viet Nam) has formally granted a Family 4 patent for Recce's Anti-Infectives, expiry 2041.

The Vietnamese Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably:

- **Process for preparation of RECCE® anti-infectives**
- **Use of R327/R529 for the treatment of disease, particularly in treatment of bacterial infections, viral infections and more**
- Specifically, further validating RECCE® anti-infectives from studies in **Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Diabetic Foot Infections (DFI), Burn Wounds, Lung Infections (including Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia), Urinary Tract Infections, Gonorrhoea, Influenza, SARS-CoV-2**
- **Administration by oral, inhalation, transdermal delivery or by injection (into the bloodstream, intramuscular and/or intravenous)**
- **Administration may also be supplied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery)**

This is the Company's eighth Family 4 patent, alongside some of the largest pharmaceutical markets in the world such as Australia, Canada, China, Hong Kong, Israel, Japan and Brazil with further Patent Cooperation Treaty (PCT) submissions in respective stages of review/allowed.



ASX: RCE, FSE: R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 **T** +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Recce's intellectual property portfolio is focused on protection in strategically important antibiotic markets, with Vietnam representing one of Southeast Asia's fastest-growing pharmaceutical markets. The Vietnamese pharmaceutical market is a rapidly expanding sector in Southeast Asia, valued at approximately USD \$7–8 billion and projected to surpass USD \$10 to \$16 billion by 2026¹.

Vietnam is confronting one of the region's most pressing antimicrobial resistance challenges. The country has one of the highest rates of antibiotic resistance in Asia, with 71% of people resistant to Penicillin and 92% to Erythromycin² (an antibiotic used to treat or prevent various bacterial infections, such as those of the respiratory tract and skin). Furthermore, Vietnam faces a high rate of drug-resistant bacteria, with hospitals in the south reporting multidrug resistance rates of 74.6% for *Escherichia coli*, ~60% for *Klebsiella pneumoniae*, and 90% for *Acinetobacter baumannii*³. These findings reinforce the urgent need for novel anti-infective therapies capable of addressing multidrug-resistant pathogens..

Recce Pharmaceuticals' Chief Executive Officer, James Graham said: “We welcome the grant of this patent by the Intellectual Property Office of Vietnam, which further strengthens Recce’s global intellectual property portfolio and expands our intellectual property footprint across Southeast Asia. This represents another important milestone in safeguarding our platform technology across strategically important markets in the region. As antibiotic resistance continues to pose a significant global health challenge, expanding our patent coverage supports our strategy to advance and commercialise our novel anti-infective platform worldwide.”

This announcement has been approved for release by Recce Pharmaceuticals Board.

¹ <https://www.trade.gov/market-intelligence/vietnam-pharmaceutical-industry-updates>

² <https://icars-global.org/projects/aquaculture-vietnam/>

³ <https://pmc.ncbi.nlm.nih.gov/articles/PMC12322788/>

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

Media and Investor Relations

Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia
Andrew Geddes
Seed Media
andrew@seedmedia.com.au

USA & Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com